ImmuCell Corporation (NASDAQ:ICCC) Files An 8-K Submission of Matters to a Vote of Security Holders
Item 5.07. Submission of Matters to a Vote of Security Holders
The 2017 Annual Meeting of Stockholders of ImmuCell Corporation
(the Company) was held at the Companys office at 56 Evergreen
Drive, Portland, Maine 04103 on Wednesday, June 14, 2017, at 3:00
p.m. Eastern Time, for the following purposes:
| 1. |
To elect to one-year terms as Directors of the Company the nominees listed in the Companys Proxy Statement dated April 28, 2017. |
|
| 2. |
To approve a nonbinding advisory resolution on the Companys executive compensation program. |
|
| 3. | To approve the Companys 2017 Stock Option and Incentive Plan. | |
| 4. |
To ratify the Audit Committees selection of RSM US LLP as the Independent Registered Public Accounting Firm of the Company for the year ending December 31, 2017. |
At the Annual Meeting, there were present in person or by proxy
3,521,952 shares of the Companys common stock, representing 73%
of the total outstanding eligible votes. The final voting results
for each proposal are as follows:
| 1. |
To elect to one-year terms as Directors of the Company the nominees listed in the Companys Proxy Statement dated April 28, 2017: |
| For | Withheld | Broker non-votes | ||||||||||
| Michael F. Brigham | 1,859,178 | 34,910 | 1,627,864 | |||||||||
| Bobbi Jo Brockmann | 1,630,387 | 263,701 | 1,627,864 | |||||||||
| Joseph H. Crabb | 1,857,546 | 36,542 | 1,627,864 | |||||||||
| David S. Cunningham | 1,142,202 | 751,886 | 1,627,864 | |||||||||
| Linda Rhodes | 1,348,653 | 545,435 | 1,627,864 | |||||||||
| Jonathan E. Rothschild | 1,347,303 | 546,785 | 1,627,864 | |||||||||
| David S. Tomsche | 1,630,309 | 263,779 | 1,627,864 | |||||||||
| Paul R. Wainman | 1,346,803 | 547,285 | 1,627,864 | |||||||||
On the basis of this vote, each of the eight nominees were
elected to one-year terms as Directors of the Company.
|
To approve a nonbinding advisory resolution on the Companys executive compensation program: |
| For | Against | Abstain | Broker non-votes | |||||||||||
| 1,798,908 | 49,825 | 45,355 | 1,627,864 | |||||||||||
95% of the shares voting on this item voted in favor. On the
basis of this vote, the nonbinding advisory resolution on the
Companys executive compensation plan was approved.
| 3. | To approve the Companys 2017 Stock Option and Incentive Plan: |
| For | Against | Abstain | Broker non-votes | |||||||||||
| 1,796,933 | 57,864 | 39,291 | 1,627,864 | |||||||||||
95% of the shares voting on this item voted in favor. On the
basis of this vote, the 2017 Stock Option and Incentive Plan was
approved.
|
To ratify the Audit Committees selection of RSM US LLP as the Independent Registered Public Accounting Firm of the Company for the year ending December 31, 2017: |
| For | Against | Abstain | ||||||||
| 2,505,405 | 1,410 | 1,015,137 | ||||||||
71% of the shares voting on this item voted in favor. On the
basis of this vote, the Audit Committees selection of RSM US LLP
as the Independent Registered Accounting Firm of the Company for
the year ending December 31, 2017 was ratified.
About ImmuCell Corporation (NASDAQ:ICCC)
ImmuCell Corporation is an animal health company. The Company operates in the development, acquisition, manufacture and sale of products that improve the health and productivity of cows for the dairy and beef industries segment. The Company has developed products that provide immediate immunity to newborn dairy and beef cattle, and is developing product line extensions of its existing products that address mastitis. The Company’s lead product, First Defense, is manufactured from cows’ colostrum utilizing its vaccine and milk protein purification technologies. Its Wipe Out Dairy Wipes are made from a non-woven fabric that allows for a vigorous cleaning. It also developed California Mastitis Test (CMT), which is used for bulk tank, as well as individual cow sample monitoring and is used to determine which quarter of the udder is mastitic. Its product development initiative is Mast Out, a Nisin-based intramammary treatment of subclinical mastitis in lactating dairy cows.
